注射用黄芪多糖辅助治疗小细胞肺癌的临床研究

Clinical study of injectable Astragalus Polysaccharides as an adjuvant therapy for small cell lung cancer

目的探讨注射用黄芪多糖辅助治疗小细胞肺癌(SCLC)的临床疗效。方法依据治疗方式的不同将50例SCLC患者分为对照组和观察组,每组25例,对照组患者给予依托泊苷^(+)顺铂(EP)方案化疗,观察组患者给予EP方案化疗联合注射用黄芪多糖治疗。比较两组患者的临床疗效、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、血液学指标[白细胞计数、神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)]和不良反应发生情况。结果观察组患者的疾病控制率(DCR)为88.00%,高于对照组患者的64.00%,差异有统计学意义(P﹤0.05)。治疗后,观察组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于本组治疗前和对照组,CD8^(+)水平均低于本组治疗前和对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CEA、NSE水平和白细胞计数均低于本组治疗前,观察组患者CEA、NSE水平均低于对照组,白细胞计数高于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为16.00%,明显低于对照组患者的60.00%,差异有统计学意义(P﹤0.01)。结论注射用黄芪多糖辅助治疗SCLC,可提高疗效,改善患者的免疫功能,且不会增加不良反应。

Objective To analyze the clinical efficacy of injectable Astragalus Polysaccharides as an adjuvant therapy for small cell lung cancer(SCLC).Method According to different treatment methods,50 patients with SCLC were divided into control group and observation group,with 25 cases in each group.The patients in the control group received etoposide^(+)cisplatin(EP)regimen chemotherapy,while the patients in the observation group received EP regimen chemotherapy combined with injectable Astragalus Polysaccharides.The clinical efficacy,immune function indicators(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),hematologic indicators[white blood cell count,neuron specific enolase(NSE)and carcinoembryonic antigen(CEA)]and incidence of adverse reactions were compared between the two groups.Result The disease control rate(DCR)of the observation group was 88.00%,which was higher than 64.00%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in the observation group were higher than those before treatment and the control group,and the level of CD8^(+)was lower than those before treatment and the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of CEA,NSE,and white blood cell count in both groups were lower than those before treatment,the levels of CEA and NSE in the observation group were lower than those in the control group,and white blood cell count was higher than that in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 16.00%,which was significantly lower than 60.00%in the control group,and the difference was statistically significant(P<0.01).Conclusion Injectable Astragalus Polysaccharides as an adjuvant therapy for SCLC can improve the therapeutic effect and immune function,and do not increase adverse reactions.